Business
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines\nThis represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs \nLONDON, March 25, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals (\"GW\") – a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines – today announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne.\n\n \n \n \n \n \n \n\n \nThe new state-of-the-art facility will be approximately 60,000 sq. ft, with an investment of over $100 million (approximately £75m). Once operational, the facility will create more than 100 highly skilled new jobs. Due to open in 2024, the facility is designed to support the company's two regulatory-approved cannabis-based medicines and support future capacity for new medicines under development. Jazz currently manufactures the extract, active pharmaceutical ingredients and the formulated drug products at KSP, occupying 12 buildings with more than 400 employees, making it, and the UK, the heart of our global cannabinoid manufacturing operations.\nThe new facility has been designed with careful consideration to the environment, and this will continue through its build phase and use. Animal refuge boxes will be installed to promote wildlife in the local area, the use of single use plastics will be minimised and more than 1,100 solar panels will be installed to provide a portion of the building's energy usage.\n\"The UK has been our home for over two decades. This strategic investment underlines Jazz's continued commitment to the UK and will help us bring potentially life-changing medicines to more patients who desperately need them in the UK and around the world,\" said Chris Tovey, executive vice president, chief operating officer and managing director, Europe & International at Jazz Pharmaceuticals. \"We are thrilled to have commenced construction of this state-of-the-art facility in Kent, which will create more than 100 permanent, highly skilled jobs. This facility, wh...